Dova Pharmaceuticals (DOVA) Posts Earnings Results, Beats Estimates By $0.12 EPS

Dova Pharmaceuticals (NASDAQ:DOVA) released its quarterly earnings results on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.12, Fidelity Earnings reports. The firm had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $2.66 million.

Shares of DOVA stock traded down $2.41 during trading hours on Friday, reaching $16.89. 647,924 shares of the stock were exchanged, compared to its average volume of 144,409. Dova Pharmaceuticals has a 12-month low of $16.63 and a 12-month high of $37.00. The company has a current ratio of 13.19, a quick ratio of 13.14 and a debt-to-equity ratio of 0.17. The stock has a market cap of $527.66 million, a PE ratio of -12.06 and a beta of 0.87.

A number of equities analysts recently commented on the stock. BidaskClub cut shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 2nd. Zacks Investment Research cut shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 30th. Raymond James assumed coverage on shares of Dova Pharmaceuticals in a research note on Wednesday, August 29th. They set an “outperform” rating and a $44.00 price target for the company. Finally, Leerink Swann dropped their price target on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating for the company in a research note on Tuesday, September 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $33.20.

In related news, CEO Alex Sapir acquired 21,700 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was bought at an average price of $22.83 per share, for a total transaction of $495,411.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 55.50% of the company’s stock.

An institutional investor recently raised its position in Dova Pharmaceuticals stock. Bank of New York Mellon Corp boosted its stake in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 196.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,374 shares of the company’s stock after buying an additional 30,750 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.16% of Dova Pharmaceuticals worth $1,387,000 as of its most recent SEC filing. 36.64% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Dova Pharmaceuticals (DOVA) Posts Earnings Results, Beats Estimates By $0.12 EPS” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/10/dova-pharmaceuticals-dova-posts-earnings-results-beats-estimates-by-0-12-eps.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Recommended Story: What do investors mean by earnings per share?

Earnings History for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply